{
  "ticker": "LLY",
  "target_date": "2024-12-19",
  "actual_date": "2024-12-19",
  "collected_at": "2025-12-08T11:10:15.453392",
  "price": {
    "open": 759.44,
    "high": 767.25,
    "low": 746.83,
    "close": 751.931396484375,
    "volume": 4032600,
    "change_1d_pct": -0.94,
    "change_7d_pct": -5.26,
    "change_30d_pct": -2.27
  },
  "technicals": {
    "rsi_14": 34.57,
    "sma_20": 782.74,
    "sma_50": 817.74,
    "macd": -11.275,
    "macd_signal": -9.479,
    "macd_histogram": -1.796,
    "bb_upper": 832.1,
    "bb_lower": 733.38,
    "price_vs_sma20_pct": -3.94,
    "price_vs_sma50_pct": -8.05,
    "volume_ratio": 1.15
  },
  "fundamentals": {
    "market_cap": 890486390784,
    "pe_ratio": 48.66928,
    "forward_pe": 43.83672,
    "price_to_book": 37.399853,
    "price_to_sales": 14.986358,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.67,
    "pct_from_52w_low": 59.25
  },
  "macro": {
    "spy": {
      "price": 579.06,
      "change_1d_pct": -0.03,
      "change_7d_pct": -3.52
    },
    "vix": {
      "level": 24.09,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.57
    },
    "dollar_index": {
      "level": 108.41
    },
    "gold": {
      "price": 2592.2
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Jim Cramer on Eli Lilly and Company (LLY): \u2018I See Things Going Back To Normal For Eli Lilly\u2019",
      "source": "Yahoo",
      "datetime": 1734643331,
      "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors ",
      "url": "https://finnhub.io/api/news?id=fe15d8c9a1f95ef355f7f10db2ef445f499fc7f5f2ddda3ec7b0edd573d066cc"
    },
    {
      "headline": "Novo Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal",
      "source": "Yahoo",
      "datetime": 1734643260,
      "summary": "Henrik Wulff, the man in charge of product supply at  Novo Nordisk  just spent $11 billion to try to fill an ocean.  Novo has handed Wulff one of the most complex jobs in all of pharmaceuticals.  Novo and its competitor  Eli Lilly  have gone to greater and greater lengths to speed their GLP-1 output",
      "url": "https://finnhub.io/api/news?id=374a0f9e8a285ac4fc8b49dd0140eac8081102a055ad70cf935c273c31a1fa4b"
    },
    {
      "headline": "Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls",
      "source": "Yahoo",
      "datetime": 1734642200,
      "summary": "Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's (LLY) weight loss drug, Zepbound, has been resolved. The stock falls in anticipation of lower demand as the supply of GLP-1 weight-loss drugs improves. Julie Hyman and J",
      "url": "https://finnhub.io/api/news?id=359954fd3484bb1e77ea0c6a15497f15c6dce5fc6b393de9b1397c1f45c5fe0e"
    },
    {
      "headline": "FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next",
      "source": "Yahoo",
      "datetime": 1734641827,
      "summary": "The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.",
      "url": "https://finnhub.io/api/news?id=6980ca3a9cb645f8c2fd0952096a961b6393aabc89c27e572e0161c42dbecb9f"
    },
    {
      "headline": "In weight loss battle, Novo and Lilly face growing offensive from licenced copies",
      "source": "Finnhub",
      "datetime": 1734638586,
      "summary": "As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a...",
      "url": "https://finnhub.io/api/news?id=ac88d93bc7156cf9bb384701347400f6e694aa216eb6b9fd40d02cee9c94939f"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}